Neuroblastoma (NB) is an embryonal tumor arising from the sympathetic central nervous system. The epidermal growth factor (EGF) plays a role in NB growth and metastatic behavior. Recently, we have demonstrated that cathepsin D (CD) contrasts EGF-induced NB cell growth in 2D by downregulating EGFR/MAPK signaling. Aggressive NB is highly metastatic to the bone and the brain. In the metastatic process, adherent cells detach to form clusters of suspended cells that adhere once they reach the metastatic site and form secondary colonies. Whether CD is involved in the survival of metastatic NB clones is not known. Therefore, in this study, we addressed how CD differentially affects cell growth in suspension versus the adherent condition. To mimic tumor heterogeneity, we co-cultured transgenic clones silenced for or overexpressing CD. We compared the growth kinetics of such mixed clones in 2D and 3D models in response to EGF, and we found that the Over CD clone had an advantage for growth in suspension, while the CD knocked-down clone was favored for the adherent growth in 2D. Interestingly, on switching from 3D to 2D culture conditions, the expression of E-cadherin and of N-cadherin increased in the KD-CD and Over CD clones, respectively. The fact that CD plays a dual role in cancer cell growth in 2D and 3D conditions indicates that during clonal evolution, subclones expressing different level of CD may arise, which confers survival and growth advantages depending on the metastatic step. By searching the TCGA database, we found up to 38 miRNAs capable of downregulating CD. Interestingly, these miRNAs are associated with biological processes controlling cell adhesion and cell migration. The present findings support the view that during NB growth on a substrate or when spreading as floating neurospheres, CD expression is epigenetically modulated to confer survival advantage. Thus, epigenetic targeting of CD could represent an additional strategy to prevent NB metastases.
NKX3-2, a transcriptional repressor factor belonging to the NK family of homeobox-containing proteins, has been widely studied for its role in promoting chondrogenic differentiation and homeostasis. NKX3-2 is upregulated in chemoresistant ovarian tumors and metastatic gastric cancer cells; however, its prognostic role and mechanistic involvement in cancer cell biology remain to be elucidated. By interrogating the TCGA database, we found that cancer patients with high NKX3-2 expression had a shorter overall survival rate than patients with low expression. In ovarian cancer patients, NKX3-2 negatively correlates with P53. Given the prominent role of the latter oncosuppressor in controlling DNA repair and cell death, here we investigate the molecular mechanism involved in this negative correlation in several ovarian cancer cell lines expressing different levels of the two proteins. We found that the high expression of endogenous or ectopic P53 reduced NKX3-2 protein expression, while its knockdown increased it. In contrast, the genetic manipulation of NKX3-2 expression did not affect P53 expression. Mechanistically, P53-mediated downregulation of NKX3-2 does not entail transcriptional activity or proteasomal clearance but occurs via P53–NKX3-2 protein–protein interaction, which in turn results in P53-induced NKX3-2 degradation via the autophagy–lysosome pathway. Remarkably, patients bearing a tumor characterized by low NKX3-2 and high MAP1LC3B expression (indicative of active autophagy) display a better prognosis. Taken together, our data indicate that NKX3-2 represents a negative prognostic factor under P53 control in ovarian cancer. From a translational point of view, identifying this novel mechanism may represent a new molecular signature capable of predicting the clinical outcome of patients, a crucial aspect of developing personalized therapeutic approaches.
PTEN is a well-established tumor suppressor that plays a central role in the regulation of cell growth, metabolism, and survival. As a protein-lipid dual phosphatase, PTEN negatively regulates the PI3K/AKT signaling pathway, which in turn modulates autophagy, a conserved catabolic process that allows cells to degrade and recycle intracellular components, through the downstream effector mTORC1. While this represents the canonical mechanism by which PTEN influences autophagy, here we show that PTEN also regulates autophagy through an alternative, AKT-independent pathway. Specifically, through genetic manipulations of PTEN expression in thyroid cancer cells, we identify BECLIN-1 as a direct target of PTEN protein phosphatase activity. PTEN physically associates with BECLIN-1 under both basal and nutrient-deprived conditions, promoting its dephosphorylation at serine 295, thus relieving AKT inhibition resulting in autophagy activation. This regulatory event correlates with increased autophagic flux under starvation, as reflected by enhanced LC3 I to LC3 II conversion. Importantly, BECLIN-1 dephosphorylation is mediated by PTEN protein phosphatase activity and does not require its lipid phosphatase function. Furthermore, bioinformatic analyses reveal that high PTEN expression, together with enhanced autophagic activity (MAP1LC3B), is associated with improved clinical outcome in cancer patients. These findings uncover a direct, AKT-independent mechanism by which PTEN controls autophagy by modulating BECLIN-1 phosphorylation status. Together, our results provide novel insight into how PTEN coordinates cellular adaptation to metabolic stress and highlight an additional pathway through which PTEN regulates the autophagic machinery in cancer cells.